Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

RationaleMultidose Dry Powder Inhalers (DPIs) are common in asthma and COPD treatment. An inherent disadvantage of DPIs is sensitivity to humidity. In real-life, DPIs are periodically exposed to humid conditions, which may affect aerosol characteristics and lung deposition. The present study compared DPI aerosol performance after exposure to humidity.MethodsBudesonide DPIs (200 µg/dose, 200 doses [Pulmicort Turbuhaler; Novopulmon Novolizer; Giona Easyhaler]) were stored in humid conditions (ambient temperature [21°C]; 75% relative humidity) for 3 months. Budesonide delivered (DD) and fine particle dose (FPD) were tested in vitro pre- and post-storage by liquid chromatography at the airflow rate obtained at 4 kPa pressure drop. A decrease > 20% in DD and FPD in vitro was defined as clinically relevant.ResultsBoth DD and FPD were virtually unchanged after 3 month's storage for Pulmicort Turbuhaler and Novopulmon Novolizer. For Giona Easyhaler these decreased by 10% and 43% respectively, a decrease that was observed already after 6 weeks storage.Delivered and fine particle dose



NT=Not testedConclusionsThis study identified a clinically relevant difference in humidity resistance. After storage, Giona Easyhaler showed a decrease in both DD and FPD in contrast to the other two DPIs. Impaired inhalation aerosol performance may lead to decreased drug delivery to the lungs, affecting clinical outcomes and safety.Sponsor: AstraZeneca.


Rating:

Share or cite this content

Citations should be made in the following way:
Thomas LÖÖf (Mölndal, Sweden), Thomas Lööf, Gunilla Telg, Georgios Stratelis, Jan-Olof Svensson. Difference in resistance to humidity between commonly used dry powder inhalers. Eur Respir J 2015; 46: Suppl. 59, 1022

Member's Comments

No comment yet.

Related content which might interest you: In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Equivalence testing of salbutamol dry powder inhalers by in vitro impaction Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001 Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 Dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI) Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI) Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Innovative and precise aerodynamic concept of a multidose dry powder inhaler (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004 In-use performance of sofotec´s dry powder inhaler Source: Eur Respir J 2004; 24: Suppl. 48, 584s Year: 2004 Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Development of a powder for inhalation with R,R-Glycopyrrolate as active ingredient for the delivery from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003 Patient preference amongst different dry powder inhalers (DPI) Source: Eur Respir J 2002; 20: Suppl. 38, 621s Year: 2002 Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 An in vitrocomparison of two dry powder inhalers after storage in hot and humid conditions Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003 Acceptability of two dry powder inhalers in 645 asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005